Skip to main content
SpringerLink
Log in

The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374) — Equipotent to PGI2 in vitro

  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Summary

The vascular and antiplatelet activities of a new, chemically stable carbacyclin derivative (ZK 36 374) were investigated and compared to PGI2.

ZK 36 374 dose-dependently relaxed bovine coronary artery strips in vitro but was without direct effects on strips of bovine coronary veins which were contracted by PGI2.

ZK 36 374 dose-dependently inhibited the ADP-, thrombin- and collagen-induced platelet aggregation in human platelet-rich plasma and disperded preformed platelet aggregates in whole blood of cats ex vivo. The IC50 was 0.2–1.1 (antigaggregation) and 13 (disaggregation) nM, respectively, and in the same range as PGI2.

The maximum antiplatelet dose of ZK 36 374 (resolution of platelet aggregates) in anaesthetized cats in vivo was 0.45 nmoles/kg x min, and could be increased up to 3 nmoles/kg x min, i.e. 6–7-fold without significant changes in arterial blood pressure and heart rate. This indicates an appreciable dissociation between antiplatelet and blood pressure-lowering activities of this compound, at least in this model.

It is concluded that ZK 36 374 is the first, chemically stable prostacyclin-mimetic agent that is equipotent to PGI2 in vitro and might be superior to PGI2 in vivo because of a reduced blood pressure-lowering activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aiken JW, Shebuski RJ (1980) Comparison in anaesthetized dogs of the anti-aggregatory and hemodynamic effects of prostacyclin and a chemically stable prostacyclin analog. 6α-carba-PGI2 (Carbacyclin). Prostaglandins 19:629–643

    Google Scholar 

  • Ceserani R, Grossoni M, Longiave D, Mizzotti B, Pozzi O, Dembinska-Kiec A, Bianco S (1980) dl-9α-deoxy.-9α-methylene-PGI2 (A stable prostacyclin derivative): Preliminary pharmacological data. Prostaglandins Med 5:131–139

    Google Scholar 

  • Fried J, Mitra DK, Nagarajan M, Mehrota MM (1980) 10,10-Difluoro-13-dehydroprostacyclin: A chemically and metabolically stabilized potent prostacyclin. J Med Chem 23:234–237

    Google Scholar 

  • Johnson RA, Morton DR, Kinner JH, Gorman RR, McGuire JC, Sun FF, Whittaker N, Bunting S, Salmon JA, Moncada S, Vane JR (1976) The chemical characterization of prostaglandin X (prostacyclin). Prostaglandins 12:915–928

    Google Scholar 

  • Langer SZ, Trendelenburg U (1969) The effect of a saturable uptake mechanism on the slopes of dose-response curves for sympathomimetic amines and on the shifts of dose-response curves produced by a competitive antagonist. J Pharmacol Exp Ther 167:117–143

    Google Scholar 

  • Lefer AM, Ogletree ML, Smith JB, Silver MJ, Nicolaou KC, Barnette WE, Gasic CP (1978) Prostacyclin: A potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science 200:52–54

    Google Scholar 

  • Lefer AM, Trachte GJ, Smith JB, Barnette W, Nicolaou KC (1979) Circulatory and platelet actions of 6,9-thiaprostacyclin (PGI2-S) in the cat. Life Sci 25:259–264

    Google Scholar 

  • Levy JV (1978) Contractile responses to prostacyclin (PGI2) of isolated human saphenous and rat venous tissue. Prostaglandins 16:93–97

    Google Scholar 

  • Moncada S, Vane JR (1979) Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmacol Rev 30:293–331

    Google Scholar 

  • Morton DR, Bundy GL, Nishizawa EE (1979) Five-membered ringmodified prostacyclin analogs. In: Vane JR, Bergström S (eds) Prostacyclin. Raven Press, New York, p 31

    Google Scholar 

  • Nicolaou KC, Barnette WE, Gasic CP, Magolda RL (1977) 6,9-Thiaprostacyclin. A stable and biologically potent analogue of prostacyclin (PGI2). J Am Chem Soc 99:7736–7738

    Google Scholar 

  • Ohlendorf R, Perzborn E, Schrör K (1980) Prevention of infarctioninduced decrease in circulating platelet count by prostacyclin. Thromb Res 19:447–453

    Google Scholar 

  • Quilley CP, McGiff JC, Lee WH, Sun FF, Wong PY-K (1980) 6-keto-PGE1: A possible metabolite of prostacyclin having platelet antiaggregatory effects. Hypertension 2:524–528

    Google Scholar 

  • Radegran K, Papaconstantinou C (1980) Prostacyclin infusion during cardiopulmonary bypass in man. Thromb Res 19:267–270

    Google Scholar 

  • Rosenkranz B, Fischer C, Reimann I, Weimer KE, Beck G, Frölich JC (1980) Identification of the major metabolite of prostacyclin and 6-keto-prostaglandin F1α in man. Biochim Biophys Acta 619:207–213

    Google Scholar 

  • Schölkens BA, Bartmann W, Beck G, Lerch U, Konz E, Weithmann U (1980) Vasodilator and antiplatelet activities of prostacyclin with modified ω-side chain: In: Samuelsson B, Ramwell PW, Paoletti R (eds) Adv. in prostaglandin and thromboxane res. vol 6. Raven Press, New York, p 341

    Google Scholar 

  • Schrör K (1979) The action of the dihydro derivatives of prostacyclin-(6R) PGI1 and (6S) PGI1 on the heart and the coronary vasculature. Naunyn-Schmiedeberg's Arch Pharmacol 306:213–217

    Google Scholar 

  • Schrör K, Link H-B, Rösen R, Klaus W, Rösen P (1980) Prostacyclininduced coronary vasodilation. Interactions with adenosine, cyclic AMP and energy charge in the rat heart in vitro. Eur J Pharmacol 64:341–348

    Google Scholar 

  • Schrör K, Moncada S (1979) Effects of prostacyclin on coronary circulation, heart rate and myocardial contractile force in isolated hearts of guinea pig and rabbit — comparison with prostaglandin E2 Prostaglandins 17:367–373

    Google Scholar 

  • Sun FF, Taylor BM (1978) Metabolism of prostacyclin in rat. Biochemistry 17:4096–4101

    Google Scholar 

  • Szczeklik A, Gryglewski RJ, Nizankowski R, Skawiński S, Gluszko P, Korbut R (1980) Prostacyclin therapy in peripheral arterial disease. Thromb Res 19:191–199

    Google Scholar 

  • Webster J, Rees AJ, Lewis PJ, Hensby CN (1980) Prostacyclin deficiency in haemolytic-uraemic syndrome. Br Med J 281:271

    Google Scholar 

  • Whittle BJR, Boughton-Smith NK (1979) 16-Phenoxy prostacyclin analogs — potent selective antiulcer compounds. In: Vane JR, Bergström S (eds), Prostacyclin. Raven Press, New York, p 159

    Google Scholar 

  • Whittle BJR, Moncada S, Whiting F, Vane JR (1980) Carbacyclin a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins 19:605–627

    Google Scholar 

  • Wong PY-K, Sun FF, McGiff JC (1978) Metabolism of prostacyclin in blood vessels. J Biol Chem 253:5555–5557

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut der Universität zu Köln, Gleueler Strasse 24, D-5000, Köln 41, Federal Republic of Germany

    K. Schrör, H. Darius, R. Matzky & R. Ohlendorf

Authors
  1. K. Schrör
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Darius
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Matzky
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Ohlendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schrör, K., Darius, H., Matzky, R. et al. The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374) — Equipotent to PGI2 in vitro. Naunyn-Schmiedeberg's Arch. Pharmacol. 316, 252–255 (1981). https://doi.org/10.1007/BF00505658

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00505658

Key words

Search

Navigation